Annals of Hematology 2014-12-01

Vitamin D deficiency and its correction in children with sickle cell anaemia.

Clare Wykes, Anita Arasaretnam, Sandra O'Driscoll, Laura Farnham, Caje Moniz, David C Rees

Index: Ann. Hematol. 93(12) , 2051-6, (2014)

Full Text: HTML

Abstract

Vitamin D deficiency is common in sickle cell anaemia (SCA, HbSS), although its significance and optimal means of correction are unknown. We conducted an audit to assess the clinical significance of 25-hydroxy vitamin D (25-OHD) deficiency in children with SCA and to evaluate two methods of vitamin D supplementation. We audited 25-OHD levels in 81 children with SCA and looked for statistical associations with biochemical, haematological and clinical parameters. In a separate group of regularly transfused children with SCA, we compared changes in 25-OHD blood concentrations following treatment with either high-dose intramuscular ergocalciferol (n = 15) or 4 days of high-dose oral cholecalciferol (n = 64). Ninety-one percent of children with SCA had 25-OHD levels <20 μg/L. The 25-OHD levels were negatively correlated with increasing age (P < 0.001) but showed no significant relationship to laboratory measurements, transcranial Doppler velocities or hospital attendance. Both intramuscular ergocalciferol and oral cholecalciferol supplementations resulted in increases of 25-OHD blood concentration to normal levels. The mean dose of ergocalciferol was greater than that of cholecalciferol (7,729 versus 5,234 international units (IU)/kg, P < 0.001), but the increment in 25-OHD levels was significantly greater in the oral cholecalciferol group (6.44 versus 2.82 (ng/L)/(IU/kg), P < 0.001). Both approaches resulted in vitamin D sufficiency for about 120 days. Increased 25-OHD concentration was significantly associated with increased serum calcium concentration. Vitamin D deficiency is very common in SCA and can be effectively corrected with high-dose intramuscular ergocalciferol or 4 days of high-dose oral cholecalciferol. Prospective, randomised studies are needed to assess the clinical value of vitamin D supplementation.


Related Compounds

  • 3-[2-[1-(6-hydroxy...
  • Native Bovine Alk...
  • Vitamin D3
  • Calcifediol
  • Calcifediol

Related Articles:

Dietary resistant starch prevents urinary excretion of 25-hydroxycholecalciferol and vitamin D-binding protein in type 1 diabetic rats.

2013-07-01

[J. Nutr. 143(7) , 1123-8, (2013)]

25-hydroxvitamin D3 promotes the long-term effect of specific immunotherapy in a murine allergy model.

2014-08-01

[J. Immunol. 193(3) , 1017-23, (2014)]

Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.

2014-10-10

[J. Clin. Oncol. 32(29) , 3242-8, (2014)]

[Severe hypercalcemia after substitution of prolonged deficiency of vitamin D in a patient with primary hyperparathyroidism].

2014-12-01

[Presse Med. 43(12 Pt 1) , 1391-4, (2014)]

Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D₃-fortified bread and milk during winter in Denmark.

2015-01-01

[Am. J. Clin. Nutr. 101(1) , 218-27, (2015)]

More Articles...